Company Overview and News
SEMBCORP Industries on Wednesday announced that its 225-megawatt gas-fired Sembcorp Myingyan Independent Power Plant (IPP) in Mandalay, Myanmar, has successfully commenced full commercial operation following its first phase operation in May this year.
IFK IFX ATB U96 SCRPF O39 SCRPY
SINGAPORE (Oct 1): Oversea-Chinese Banking Corporation (OCBC Bank) says the sale of its 33.33% stake in Hong Kong Life Insurance has been terminated.
SINGAPORE: Oversea-Chinese Banking Corp (OCBC) said on Monday (Oct 1) that a planned sale of Hong Kong Life Insurance to investment firm First Origin had been called off after the buyer failed to meet certain conditions before a Sep 30 deadline.
CGHBF O39 1111
FOR the five trading sessions ended Sep 27, the Straits Times Index (STI) climbed 1.8 per cent, with the Nikkei 225, Hang Seng and S&P/ASX 200 Indices averaging a 0.3 per cent gain.
C9Q 5UX SLVFF B73 BLH CDEVY O39 U10 5IC C09 L23 K2LU 5CP CDEVF E6R
KUALA LUMPUR (Sept 26): Singapore Press Holdings Ltd and an arm of Keppel Corp are considering making a general offer for the shares they don’t already own in the city-state’s smallest wireless operator, M1 Ltd, people with knowledge of the matter said.
TPGTF SGPRY 6888 SGPRF TPPTY SGAPY SRHBF TPM AXXTF SRHBY SNGNF O39
SINGAPORE (Sept 25): The digital transformation efforts of Oversea-Chinese Banking Corp is a necessity rather than a competitive advantage for the lender.
Singapore is small but exceedingly wealthy, with rock-solid government finances. It's also in a strategic location in Asia, the world's fastest-growing region. The stock market is down this year and the index looks attractively priced… on the face of it. Is now a good time to buy Singaporean stocks?
SINGAPORE: Singapore-listed companies have been repurchasing more of their own shares this year, with stock buybacks hitting a near three-year high last month, and analysts think this trend could continue for the rest of 2018 amid a volatile market.
SPXCY UOVEF SPXCF C09 UOVEY CDEVF CDEVY U11 O39 S68
(Sept 12): Southeast Asian stock markets ended on a cautious note on Wednesday, as broader Asian peers hit a 14-month low, amid worries of intensifying Sino-U.S. trade war, with Philippine shares extending losses to a sixth straight session.
ABTZY AEV O39
BENGALURU (Sept 4): Indonesian shares slid and most other Southeast Asian markets slipped on Tuesday as Argentina's austerity measures rattled emerging markets and led to steep losses in most Asian currencies.
DBSDY D05 DBSDF O39
2018-09-03 theedgemarkets - 1
Competition to manage the money of Asia’s burgeoning army of millionaires has pushed pay hikes for wealth managers to the highest in more than a decade. Those willing to jump to a rival are getting increases of 30 percent or more in Hong Kong and Singapore, according to private bankers and recruiters.
DSLV VIIX DGLD CSSLF VIIZ CS O39 CSGKF UGLD UBS ZIV USLV TVIX ULSGF XIV
SINGAPORE: Several people have been cheated into providing their personal information and credit card details on phishing websites or over the phone, after responding to online advertisements or SMSes purportedly sent out by DBS Bank and Oversea-Chinese Banking Corporation (OCBC).
IT will be a challenging year for banks, but OCBC Bank (Malaysia) Bhd (OCBC Malaysia) is optimistic it can grow its earnings for the second straight year after hitting a record high last year.
SINGAPORE (Aug 28): Singapore’s dollar is approaching the upper boundary of its trading band as speculation mounts that the central bank will boost the exchange rate for a second time this year to combat inflation.
WBC WEBNF WBK HCS O39 HSB 0005 WBC HSEA HSEB HSBC HBCYF
SINGAPORE, Aug 28 — Singapore’s dollar is approaching the upper boundary of its trading band as speculation mounts that the central bank will boost the exchange rate for a second time this year to combat inflation.
WBC WEBNF WBK HCS O39 HSB 0005 WBC HSEA HSEB HSBC HBCYF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...